ES2229786T3 - Preparacion farmaceutica de moxifloxacina. - Google Patents

Preparacion farmaceutica de moxifloxacina.

Info

Publication number
ES2229786T3
ES2229786T3 ES99955906T ES99955906T ES2229786T3 ES 2229786 T3 ES2229786 T3 ES 2229786T3 ES 99955906 T ES99955906 T ES 99955906T ES 99955906 T ES99955906 T ES 99955906T ES 2229786 T3 ES2229786 T3 ES 2229786T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
moxifloxacin
oral administration
lactose
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99955906T
Other languages
English (en)
Spanish (es)
Inventor
Patrick Bosche
Hans Friedrich Mahler
Claus Weisemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7889824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2229786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of ES2229786T3 publication Critical patent/ES2229786T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES99955906T 1998-11-10 1999-10-29 Preparacion farmaceutica de moxifloxacina. Expired - Lifetime ES2229786T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855758 1998-11-10
DE19855758 1998-11-10

Publications (1)

Publication Number Publication Date
ES2229786T3 true ES2229786T3 (es) 2005-04-16

Family

ID=7889824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99955906T Expired - Lifetime ES2229786T3 (es) 1998-11-10 1999-10-29 Preparacion farmaceutica de moxifloxacina.

Country Status (41)

Country Link
US (1) US6610327B1 (cg-RX-API-DMAC7.html)
EP (1) EP1128831B1 (cg-RX-API-DMAC7.html)
JP (1) JP4809978B2 (cg-RX-API-DMAC7.html)
KR (1) KR100650489B1 (cg-RX-API-DMAC7.html)
CN (1) CN1149993C (cg-RX-API-DMAC7.html)
AR (1) AR021074A1 (cg-RX-API-DMAC7.html)
AT (1) ATE279193T1 (cg-RX-API-DMAC7.html)
AU (1) AU745282B2 (cg-RX-API-DMAC7.html)
BG (1) BG64974B1 (cg-RX-API-DMAC7.html)
BR (2) BRPI9915208B8 (cg-RX-API-DMAC7.html)
CA (1) CA2349161C (cg-RX-API-DMAC7.html)
CO (1) CO5070571A1 (cg-RX-API-DMAC7.html)
CU (1) CU23260B7 (cg-RX-API-DMAC7.html)
CZ (1) CZ292069B6 (cg-RX-API-DMAC7.html)
DE (1) DE59910858D1 (cg-RX-API-DMAC7.html)
DK (1) DK1128831T3 (cg-RX-API-DMAC7.html)
EE (1) EE04418B1 (cg-RX-API-DMAC7.html)
ES (1) ES2229786T3 (cg-RX-API-DMAC7.html)
HK (1) HK1042245B (cg-RX-API-DMAC7.html)
HN (1) HN1999000183A (cg-RX-API-DMAC7.html)
HR (1) HRP20010332B1 (cg-RX-API-DMAC7.html)
HU (1) HU229065B1 (cg-RX-API-DMAC7.html)
ID (1) ID29089A (cg-RX-API-DMAC7.html)
IL (2) IL142642A0 (cg-RX-API-DMAC7.html)
MA (1) MA26757A1 (cg-RX-API-DMAC7.html)
MY (1) MY121114A (cg-RX-API-DMAC7.html)
NO (1) NO319342B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ511554A (cg-RX-API-DMAC7.html)
PE (1) PE20001304A1 (cg-RX-API-DMAC7.html)
PL (1) PL194020B1 (cg-RX-API-DMAC7.html)
PT (1) PT1128831E (cg-RX-API-DMAC7.html)
RU (1) RU2230555C9 (cg-RX-API-DMAC7.html)
SI (1) SI1128831T1 (cg-RX-API-DMAC7.html)
SK (1) SK283936B6 (cg-RX-API-DMAC7.html)
SV (1) SV1999000194A (cg-RX-API-DMAC7.html)
TR (1) TR200101310T2 (cg-RX-API-DMAC7.html)
TW (1) TW580388B (cg-RX-API-DMAC7.html)
UA (1) UA72483C2 (cg-RX-API-DMAC7.html)
UY (1) UY25792A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000027398A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200103141B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
CN1330306C (zh) * 2004-08-11 2007-08-08 深圳市天一时科技开发有限公司 莫西沙星明胶胶囊剂及其制备方法
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
PL2349220T3 (pl) * 2008-10-09 2012-12-31 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny
EP2735307A1 (de) 2008-12-08 2014-05-28 Ratiopharm GmbH Kompaktiertes Moxifloxacin
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) * 2009-11-16 2013-09-11 江苏亚邦强生药业有限公司 莫西沙星口服制剂及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (en) * 2011-04-11 2012-10-17 Innocoll Technologies Limited Methods for treating bacterial infection
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) * 2011-10-14 2012-11-20 Закрытое акционерное общество "Брынцалов-А" Фармацевтический препарат моксифлоксацина
WO2013063271A1 (en) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
EP2770985A4 (en) 2011-10-25 2015-01-21 U S Phytotherapy Inc ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
WO2013081044A1 (ja) * 2011-11-30 2013-06-06 富山化学工業株式会社 1-シクロプロピル-8-(ジフルオロメトキシ)-7-[(1r)-1-メチル-2,3-ジヒドロ-1h-イソインドール-5-イル]-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸のメタンスルホン酸塩水和物含有錠剤
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) * 2012-02-21 2012-07-04 天津市汉康医药生物技术有限公司 一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
JPH01175936A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd 6.8−ジフルオロ−1−(2−フルオロエチル)−1,4−ジヒドロ−7−(4−メチル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
TW209865B (cg-RX-API-DMAC7.html) * 1992-01-10 1993-07-21 Bayer Ag
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino

Also Published As

Publication number Publication date
AU745282B2 (en) 2002-03-21
CU23260B7 (es) 2008-01-24
RU2230555C2 (ru) 2004-06-20
SV1999000194A (es) 2000-10-16
HN1999000183A (es) 1999-11-01
UY25792A1 (es) 2001-08-27
SI1128831T1 (en) 2005-04-30
ATE279193T1 (de) 2004-10-15
PL194020B1 (pl) 2007-04-30
SK283936B6 (sk) 2004-05-04
BG64974B1 (bg) 2006-11-30
PT1128831E (pt) 2005-01-31
BR9915208A (pt) 2001-07-31
DE59910858D1 (de) 2004-11-18
AU1267400A (en) 2000-05-29
JP4809978B2 (ja) 2011-11-09
HUP0104762A2 (hu) 2002-05-29
HU229065B1 (en) 2013-07-29
WO2000027398A1 (de) 2000-05-18
UA72483C2 (en) 2005-03-15
EE04418B1 (et) 2005-02-15
IL142642A0 (en) 2002-03-10
BRPI9915208B1 (pt) 2011-11-01
HK1042245B (zh) 2005-03-11
BRPI9915208A (pt) 2001-07-31
HUP0104762A3 (en) 2002-10-28
IL142642A (en) 2006-10-05
SK6102001A3 (en) 2001-12-03
KR20010089424A (ko) 2001-10-06
NO20012248L (no) 2001-06-06
NO319342B1 (no) 2005-07-18
BRPI9915208B8 (pt) 2021-07-06
HRP20010332B1 (hr) 2011-01-31
KR100650489B1 (ko) 2006-11-28
CA2349161A1 (en) 2000-05-18
CZ20011652A3 (cs) 2001-08-15
US6610327B1 (en) 2003-08-26
RU2230555C9 (ru) 2006-02-27
MY121114A (en) 2005-12-30
HK1042245A1 (en) 2002-08-09
ZA200103141B (en) 2002-05-07
JP2002529415A (ja) 2002-09-10
BG105459A (en) 2001-12-29
NO20012248D0 (no) 2001-05-07
PE20001304A1 (es) 2000-12-30
CN1149993C (zh) 2004-05-19
TR200101310T2 (tr) 2001-10-22
HRP20010332A2 (en) 2002-06-30
MA26757A1 (fr) 2004-12-20
AR021074A1 (es) 2002-06-12
CN1325306A (zh) 2001-12-05
EE200100259A (et) 2002-12-16
PL348112A1 (en) 2002-05-06
NZ511554A (en) 2003-07-25
CO5070571A1 (es) 2001-08-28
DK1128831T3 (da) 2005-01-17
EP1128831A1 (de) 2001-09-05
CZ292069B6 (cs) 2003-07-16
ID29089A (id) 2001-07-26
TW580388B (en) 2004-03-21
CA2349161C (en) 2008-01-29
EP1128831B1 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
US6610327B1 (en) Pharmaceutical moxifloxacin preparation
US9018261B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
ES2587912T3 (es) Composición farmacéutica que comprende olmesartán medoxomilo y rosuvastatina o su sal
SK52295A3 (en) Stable extended release oral dosage composition
US20140348909A1 (en) Pharmaceutical compositions of lurasidone
JPWO2002024166A1 (ja) 崩壊性が良好な経口製剤
US20130004550A1 (en) Sustained-release solid preparation for oral use
BR112018011085B1 (pt) Composição farmacêutica compreendendo doravirina, fumarato de tenofovir desoproxila e lamivudina e processo para sua preparação
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
ES2352299T3 (es) Composiciones farmacéuticas que contienen fumarato de quetiapina.
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
US20020037899A1 (en) Compositions containing an inhibitor of dihydrofolate reductase and a folate
EP2558079B1 (en) Ciprofloxacin dry syrup composition
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
CN101461799A (zh) 一种稳定的普伐他汀药物组合物及其制备方法
US20170202777A1 (en) Solid preparation
HK40045152B (en) Crystalline epinephrine malonate salt
NZ615452B2 (en) Solid preparation containing 6-((7s)-7-hydroxy-6,7-dihydro-5h-pyrrolo-[1,2-c]imidazol-7-yl)-n-methyl-2-naphthamide